Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INO Inovio Pharmaceuticals	$1.97 -2.5%	$1.80	$1.42 ▼ $12.33	$72.25M	1.4	596,317 shs	439,695 shs
SMTI Sanara MedTech	$30.39 -1.9%	$30.91	$25.86 ▼ $39.08	$275.44M	1.38	26,132 shs	27,384 shs
SNWV SANUWAVE Health	$28.55 -1.1%	$31.32	$5.17 ▼ $39.50	$244.27M	1.25	31,750 shs	56,818 shs
STIM Neuronetics	$3.99	$4.14	$0.52 ▼ $5.92	$262.62M	1.92	749,035 shs	515,955 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INO Inovio Pharmaceuticals	-2.48%	-3.90%	+5.35%	-12.05%	-82.49%
SMTI Sanara MedTech	-1.94%	-3.52%	+0.56%	-9.80%	+0.36%
SNWV SANUWAVE Health	-1.11%	-11.64%	+0.28%	+2,854,999,900.00%	+2,854,999,900.00%
STIM Neuronetics	0.00%	-5.45%	-4.77%	-3.39%	+69.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INO Inovio Pharmaceuticals	3.6446 of 5 stars	3.3	2.0	0.0	4.3	2.4	0.0	1.3
SMTI Sanara MedTech	1.7976 of 5 stars	3.5	1.0	0.0	0.0	2.0	1.7	0.6
SNWV SANUWAVE Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STIM Neuronetics	1.4376 of 5 stars	3.3	2.0	0.0	0.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	394.92% Upside
SMTI Sanara MedTech	3.00	Buy	$49.50	62.88% Upside
SNWV SANUWAVE Health	0.00	N/A	N/A	N/A
STIM Neuronetics	2.67	Moderate Buy	$5.50	37.84% Upside

Current Analyst Ratings Breakdown

Latest INO, STIM, SMTI, and SNWV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$51.00 ➝ $53.00
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
3/26/2025	SMTI Sanara MedTech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$46.00 ➝ $46.00
3/26/2025	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $51.00
3/19/2025	INO Inovio Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$6.00 ➝ $5.00
3/19/2025	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
3/5/2025	STIM Neuronetics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $8.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INO Inovio Pharmaceuticals	$283.10K	255.20	N/A	N/A	$5.16 per share	0.38
SMTI Sanara MedTech	$91.57M	2.95	N/A	N/A	$5.22 per share	5.82
SNWV SANUWAVE Health	$36.19M	6.75	N/A	N/A	N/A	∞
STIM Neuronetics	$89.45M	2.94	N/A	N/A	$1.18 per share	3.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INO Inovio Pharmaceuticals	-$135.12M	-$3.19	N/A	N/A	N/A	N/A	-118.17%	-83.47%	N/A
SMTI Sanara MedTech	-$4.30M	-$1.34	N/A	N/A	N/A	-10.71%	-19.86%	-10.91%	8/11/2025 (Estimated)
SNWV SANUWAVE Health	N/A	-$4.56	N/A	∞	N/A	N/A	N/A	N/A	N/A
STIM Neuronetics	-$30.19M	-$1.31	N/A	N/A	N/A	-50.09%	-141.24%	-32.77%	8/11/2025 (Estimated)

Latest INO, STIM, SMTI, and SNWV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SMTI Sanara MedTech	-$0.31	-$0.41	-$0.10	-$0.41	$23.48 million	$23.43 million
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
5/9/2025	Q1 2025	SNWV SANUWAVE Health	N/A	-$0.66	N/A	-$0.66	N/A	$9.34 million
5/6/2025	Q1 2025	STIM Neuronetics	-$0.13	-$0.21	-$0.08	-$0.21	$29.07 million	$31.98 million
3/25/2025	Q4 2024	SMTI Sanara MedTech	-$0.19	-$0.18	+$0.01	-$0.18	$22.75 million	$26.31 million
3/18/2025	Q4 2024	INO Inovio Pharmaceuticals	-$0.87	-$0.69	+$0.18	-$0.60	$0.03 million	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SMTI Sanara MedTech	N/A	N/A	N/A	N/A	N/A
SNWV SANUWAVE Health	N/A	N/A	N/A	N/A	N/A
STIM Neuronetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INO Inovio Pharmaceuticals	N/A	3.88	3.88
SMTI Sanara MedTech	0.76	2.23	2.02
SNWV SANUWAVE Health	N/A	N/A	N/A
STIM Neuronetics	4.90	3.16	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INO Inovio Pharmaceuticals	26.79%
SMTI Sanara MedTech	8.10%
SNWV SANUWAVE Health	42.53%
STIM Neuronetics	53.59%

Insider Ownership

Company	Insider Ownership
INO Inovio Pharmaceuticals	2.30%
SMTI Sanara MedTech	54.10%
SNWV SANUWAVE Health	36.60%
STIM Neuronetics	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	25.45 million	Optionable
SMTI Sanara MedTech	60	8.89 million	4.01 million	Not Optionable
SNWV SANUWAVE Health	40	8.56 million	N/A	N/A
STIM Neuronetics	180	65.82 million	27.37 million	Optionable

INO, STIM, SMTI, and SNWV Headlines

Recent News About These Companies

Neuronetics, Inc. (NASDAQ:STIM) EVP Sells $826,074.20 in Stock

May 15, 2025 | insidertrades.com

Balyasny Asset Management L.P. Grows Position in Neuronetics, Inc. (NASDAQ:STIM)

May 15, 2025 | marketbeat.com

Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

May 14, 2025 | tmcnet.com

Q2 EPS Estimates for Neuronetics Reduced by William Blair

May 11, 2025 | marketbeat.com

Neuronetics Announces Inducement Awards for New Team Members

May 10, 2025 | msn.com

Neuronetics, Inc. (NASDAQ:STIM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.83

May 9, 2025 | finance.yahoo.com

Neuronetics (NASDAQ:STIM) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

May 8, 2025 | marketbeat.com

Renaissance Technologies LLC Has $255,000 Position in Neuronetics, Inc. (NASDAQ:STIM)

May 8, 2025 | marketbeat.com

Earnings call transcript: Neuronetics Q1 2025 misses EPS, stock drops 22%

May 7, 2025 | investing.com

Neuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook Acquisition

May 7, 2025 | nasdaq.com

Neuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook Acquisition

May 7, 2025 | nasdaq.com

Neuronetics Inc (STIM) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Margin Challenges

May 7, 2025 | finance.yahoo.com

Neuronetics, Inc. (STIM) Q1 2025 Earnings Call Transcript

May 6, 2025 | seekingalpha.com

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

Neuronetics Reports First Quarter 2025 Financial and Operating Results

May 6, 2025 | globenewswire.com

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 5, 2025 | globenewswire.com

Neuronetics (STIM) to Release Quarterly Earnings on Tuesday

May 1, 2025 | marketbeat.com

Why Neuronetics, Inc. (STIM) is Surging in 2025

April 30, 2025 | msn.com

Neuronetics to Announce Q1 2025 Results and Host Live Conference Call on May 6

April 24, 2025 | msn.com

Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

April 22, 2025 | tmcnet.com

Neuronetics Announces Expanded Coverage for NeuroStar TMS to Treat Adolescent Depression

April 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Vertiv Crushes Q1 Estimates, Can the Stock Maintain Momentum?
By Jeffrey Neal Johnson | April 28, 2025
View Vertiv Crushes Q1 Estimates, Can the Stock Maintain Momentum?
Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan
By Jeffrey Neal Johnson | May 3, 2025
View Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan
Domino’s Pizza Builds Leverage: Analysts Raise Price Targets
By Thomas Hughes | April 29, 2025
View Domino’s Pizza Builds Leverage: Analysts Raise Price Targets

INO, STIM, SMTI, and SNWV Company Descriptions

Inovio Pharmaceuticals NASDAQ:INO

$1.97 -0.05 (-2.48%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.97 0.00 (0.00%)

As of 05/23/2025 07:59 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Sanara MedTech NASDAQ:SMTI

$30.39 -0.60 (-1.94%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$30.36 -0.03 (-0.10%)

As of 05/23/2025 04:04 PM Eastern

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

SANUWAVE Health NASDAQ:SNWV

$28.55 -0.32 (-1.11%)

As of 05/23/2025 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Neuronetics NASDAQ:STIM

$3.99 0.00 (0.00%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$4.13 +0.14 (+3.53%)

As of 05/23/2025 06:45 PM Eastern

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time